EUVIMEDEUVIMED entdecken
Crossref

Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [ 68 Ga]-Labeled Biphenyl-Containing PSMA Tracers

Yimin Chen, Xiaojun Zhang, Ming Ni, Xi Gao, Xinlin Wang, Qiang Xie iD, Jinming Zhang, Mengchao Cui iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Yimin Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Prostatic Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioisotope-labeled prostate-specific membrane antigen (PSMA) PET tracers have gained popularity in diagnosing prostate cancer (PCa). This study aimed to improve the affinity and tumor-targeting capabilities of new PSMA tracers by increasing the number of pharmacophores that specifically bind to PSMA. Using biphenyl as a core scaffold, we investigated the relationship among spacer segments, affinity, and pharmacokinetic properties. In preclinical PET studies on mice with 22Rv1 tumors, compared with [68Ga]Ga-PSMA-11 (SUVmax = 3.37), [68Ga]Ga-PSMA-D5 (Ki = 0.15) showed higher tumor uptake (SUVmax = 3.51) and lower renal uptake (T/K = 1.84). In the first-in-human study, [68Ga]Ga-PSMA-D5 effectively detected small PCa-associated lesions and distant metastases. The advantages of [68Ga]Ga-PSMA-D5 include high tumor uptake, straightforward synthesis, and labeling, making it a promising PSMA PET tracer. Furthermore, [68Ga]Ga-PSMA-D5 contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac, providing the potential for targeted radioligand therapy in PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesProstatic NeoplasmsMaleHumansAnimalsMiceRadioisotopesPositron-Emission TomographyPositron Emission Tomography Computed TomographyBiphenyl Compounds

Substanzen

Gallium RadioisotopesRadioisotopesbiphenylBiphenyl Compounds

Autor:innen und Institutionen

  • Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
  • Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Nuclear Medicine, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, China.
  • Center for Advanced Materials Research, Beijing Normal University at Zhuhai, Zhuhai 519087, China.

ORCID-Profile: Qiang Xie, Mengchao Cui

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, Y., Zhang, X., Ni, M., Gao, X., Wang, X., Xie, Q., Zhang, J., & Cui, M. (2023). Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [ 68 Ga]-Labeled Biphenyl-Containing PSMA Tracers. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01475

Vancouver

Chen Y, Zhang X, Ni M, Gao X, Wang X, Xie Q, et al. Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [ 68 Ga]-Labeled Biphenyl-Containing PSMA Tracers. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01475

BibTeX
@article{Chen2023,
  author = {Chen, Yimin and Zhang, Xiaojun and Ni, Ming and Gao, Xi and Wang, Xinlin and Xie, Qiang and Zhang, Jinming and Cui, Mengchao},
  title = {Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [ 68 Ga]-Labeled Biphenyl-Containing PSMA Tracers},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01475}
}
Kostenlos starten →